Patents by Inventor Paul J. Gilligan

Paul J. Gilligan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4- (2-butylamino) -2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-YL) pyrazolo- [1,5-A] -1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
    Publication number: 20040014760
    Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I): 1
    Type: Application
    Filed: February 5, 2003
    Publication date: January 22, 2004
    Inventor: Paul J. Gilligan
  • Imidazo[1, 2-a] pyrazines for the treatment of irritable bowel syndrome
    Publication number: 20030220342
    Abstract: Provided herein are methods for treating a subject afflicted with irritable bowel syndrome comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition that comprises a pharmaceutically acceptable carrier and a compound of the formula 1
    Type: Application
    Filed: May 1, 2003
    Publication date: November 27, 2003
    Inventors: Rajagopal Bakthavatchalam, Richard G. Wilde, Paul J. Gilligan
  • Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
    Publication number: 20030171380
    Abstract: Compounds provided herein are novel substituted pyrazinones, pyridines and pyrimidines of Formula (I) and (II): 1
    Type: Application
    Filed: May 14, 2002
    Publication date: September 11, 2003
    Inventors: Argyrios G. Arvanitis, Paul J. Gilligan, Richard A. Hartz
  • Pyrazolopyrimidines as CRF antagonists
    Publication number: 20030139426
    Abstract: The present invention relates to pyrazolopyrimidines according to formula (I) 1
    Type: Application
    Filed: April 18, 2002
    Publication date: July 24, 2003
    Inventors: Richard G. Wilde, Paul J. Gilligan
  • Imidazo[1,2-a]pyrazines for the treatment of neurological disorders
    Patent number: 6589952
    Abstract: Provided herein are novel imidazo[1,2-a]pyrazines of Formula I: wherein: X is CHR5, NR5, O, S, S(O)n or a single bond, wherein n is equal to 0, 1 or 2; D is aryl or heteroaryl attached through an unsaturated carbon atom and wherein said aryl or heteroaryl is optionally substituted at any available position with from 1-5 of A1, A2, A3, A4 and A5; R2 is C1-4 alkyl or C3-8 cycloalkyl, each of which is optionally substituted with from 1-3 hydroxy, halogen or C1-4 alkoxy, or wherein when X is a bond, R2 is optionally also CN, CF3, C2F5, C1-4 alkyl or C3-8 cycloalkyl, each of which C1-4 alkyl or C3-8 cycloalkyl is optionally substituted with from 1-3 hydroxy, halogen and C1-4 alkoxy; as well as compositions containing the same, useful in the treatment of, for example, neurological and psychological disorders characterized by corticotropin releasing factor (CRF) overexpression.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: July 8, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Rajagopal Bakthavatchalam, Richard G. Wilde, Paul J. Gilligan
  • 4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
    Publication number: 20030125330
    Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I): 1
    Type: Application
    Filed: March 6, 2002
    Publication date: July 3, 2003
    Inventor: Paul J. Gilligan
  • Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders
    Patent number: 6525056
    Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: February 25, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Argyrios G. Arvanitis, Paul J. Gilligan, James P. Beck, Rajagopal Bakthavatchalam
  • Pyrazolotriazines as CRF antagonists
    Publication number: 20020147338
    Abstract: The present invention relates to pyrazolotriazines according to formula (I) 1
    Type: Application
    Filed: November 21, 2001
    Publication date: October 10, 2002
    Inventors: Paul J. Gilligan, Richard G. Wilde
  • Imidazo[1,2-a]pyrazines for the treatment of neurological disorders
    Publication number: 20020049208
    Abstract: Provided herein are imidazo[1,2-a]pyrazines of the Formula (I): 1
    Type: Application
    Filed: July 13, 2001
    Publication date: April 25, 2002
    Inventors: Rajagopal Bakthavatchalam, Richard G. Wilde, Paul J. Gilligan
  • Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders
    Publication number: 20010025042
    Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I): 1
    Type: Application
    Filed: February 21, 2001
    Publication date: September 27, 2001
    Inventors: Argyrios Arvanitis, Paul J. Gilligan, James P. Beck, Rajagopal Bakthavatchalam
  • Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
    Patent number: 6245769
    Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.
    Type: Grant
    Filed: September 1, 1998
    Date of Patent: June 12, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Argyrios G. Arvanitis, Paul J. Gilligan, James P. Beck, Rajagopal Bakthavatchalam
  • Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
    Patent number: 6174912
    Abstract: Corticotropin releasing factor (CRF) antagonists of Formulae (I) or (II): and their use in treating psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: August 21, 1998
    Date of Patent: January 16, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: James P. Beck, Paul J. Gilligan
  • Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists
    Patent number: 6103737
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I: ##STR1## and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: August 15, 2000
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Anthony J. Cocuzza, Frank W. Hobbs, James P. Beck, Paul J. Gilligan
  • Antipsychotic nitrogen-containing bicyclic compounds
    Patent number: 5532243
    Abstract: There are provided nitrogen-containing bicyclic compounds, pharmaceutical compositions containing these compounds and methods of using these compounds to treat physiological or drug-induced psychosis or diskinesia in a mammal.
    Type: Grant
    Filed: February 14, 1992
    Date of Patent: July 2, 1996
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventor: Paul J. Gilligan
  • Treatment of psychosis using 1-cycloalkylpiperidines
    Patent number: 5296479
    Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: March 22, 1994
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • Antipsychotic 1-cycloalkylpiperidines
    Patent number: 5266572
    Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
    Type: Grant
    Filed: June 18, 1992
    Date of Patent: November 30, 1993
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • Antipsychotic 1-cycloalkylpiperidines
    Patent number: 5243048
    Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: September 7, 1993
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • Piperidine ether derivatives as psychotropic drugs or plant fungicides
    Patent number: 5169855
    Abstract: There are provided piperidine ether derivatives, pharmaceutical and agricultural compositions containing them useful for treating physiological or drug induced psychosis or dyskinesia in a mammal or fungal disease in plants. Also provided are methods for preparing these compounds.
    Type: Grant
    Filed: March 28, 1990
    Date of Patent: December 8, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • N-aralkyl piperidine derivatives as psychotropic drugs
    Patent number: 5116846
    Abstract: There are provided N-aralkyl piperidine derivatives which are selective sigma receptor antagonists. These compounds and pharmaceutical compositions containing them are useful for treating physiological or drug induced psychosis or dyskinesia in a mammal.
    Type: Grant
    Filed: March 28, 1990
    Date of Patent: May 26, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • Antipsychotic 1-cycloalkylpiperidines
    Patent number: 5109002
    Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
    Type: Grant
    Filed: August 20, 1990
    Date of Patent: April 28, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam